Колхицин: репозиционирование «античного» лекарства в XXI веке
Аннотация
Основными показаниями для лечения колхицином до недавнего времени были подагра, перикардит, семейная средиземноморская лихорадка и некоторые другие аутовоспалительные заболевания. Расширение показаний (репозиционирование) для применения колхицина в направлении профилактики кардиоваскулярных осложнений следует рассматривать как одно из крупных событий медицины XXI века. Расшифровка роли воспаления как важнейшего механизма развития атеросклероза создало предпосылки для разработки концепции противовоспалительной терапии атеросклероза, в рамках которой важное место может занять терапия низкими дозами колхицина, дополняющая эффекты аспирина, статинов и антигипертензивной терапии. Анализ материалов рандомизированных плацебо-контролируемых исследований колхицина свидетельствует о снижении частоты кардиоваскулярных осложнений у пациентов с ишемической болезнью сердца (на 31%) и у пациентов, недавно перенесших инфаркт миокарда (на 23%), а также инфаркта миокарда (на 33%), инсульта, потребности в реваскуляризации миокарда и кардиоваскулярной летальности. Применение колхицина в низкой дозе (0,5 мг/сут.) одобрено Управлением по контролю качества пищевых продуктов и лекарственных средств США для профилактики кардиоваскулярных осложнений у пациентов с ишемической болезнью сердца. Можно полагать, что в перспективе колхицин займет важное место в профилактике и лечении кардиоваскулярной патологии, связанной с атеросклеротическим поражением сосудов.
Об авторах
Е. Л. Насонов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)
Россия
Россия
115522, Москва, Каширское шоссе, 34а;
119991, Москва, ул. Трубецкая, 8, стр. 2
О. М. Драпкина
ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава России
Россия
Россия
101990, Москва, Петроверигский пер., 10
Список литературы
1. Насонов ЕЛ. Современная концепция аутоиммунитета в ревматологии. Научно-практическая ревматология. 2023;61(4):397-420. doi: 10.47360/1995-4484-2023-397-420
2. Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524-533. doi: 10.1038/s41586-021-03392-8
3. Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822-1832. doi: 10.1038/s41591-019-0675-0
4. GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2100-2132. doi: 10.1016/S0140-6736(24)00367-2
5. Насонов ЕЛ. Пандемия коронавирусной болезни 2019 (COVID-19) и аутоиммунные ревматические заболевания: итоги и перспективы. Научно-практическая ревматология. 2024;62(1):32-54. doi: 10.47360/1995-4484-2024-32-54
6. Насонов ЕЛ, Румянцев АГ, Самсонов МЮ. Фармакотерапия аутоиммунных ревматических заболеваний – от моноклональных антител к CAR-T-клеткам: 20 лет спустя. Научно-практическая ревматология. 2024;62(3):262-279. doi: 10.47360/1995-4484-2024-262-279
7. Fugger L, Jensen LT, Rossjohn J. Challenges, progress, and prospects of developing therapies to treat autoimmune diseases. Cell. 2020;181(1):63-80. doi: 10.1016/j.cell.2020.03.007
8. Roubille F, Kritikou E, Busseuil D, Barrere-Lemaire S, Tardif JC. Colchicine: An old wine in a new bottle? Antiinflamm Antiallergy Agents Med Chem. 2013;12(1):14-23. doi: 10.2174/1871523011312010004
9. Hartung EF. History of the use of colchicum and related medicaments in gout; with suggestions for further research. Ann Rheum Dis. 1954;13(3):190-200. doi: 10.1136/ard.13.3.190
10. Imazio M, Agrimi C, Cescon L, Panzolli G, Collini V, Sinagra G. Colchicine for the treatment of the spectrum of cardiovascular diseases: Current evidence and ongoing perspectives. J Cardiovasc Med (Hagerstown). 2024;25(9):653-663. doi: 10.2459/JCM.0000000000001647
11. Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis DA, Giotaki SG, et al. Colchicine in cardiovascular disease: In-depth review. Circulation. 2022;145(1):61-78. doi: 10.1161/CIRCULATIONAHA.121.056171
12. Angelidis C, Kotsialou Z, Kossyvakis C, Vrettou AR, Zacharoulis A, Kolokathis F, et al. Colchicine pharmacokinetics and mechanism of action. Curr Pharm Des. 2018;24(6):659-663. doi: 10.2174/138161282466618012
13. Stamp LK, Horsley C, Te Karu L, Dalbeth N, Barclay M. Colchicine: The good, the bad, the ugly and how to minimize the risks. Rheumatology (Oxford). 2024;63(4):936-944. doi: 10.1093/rheumatology/kead625
14. Stack J, Ryan J, McCarthy G. Colchicine: New insights to an old drug. Am J Ther. 2015;22(5):e151-e157. doi: 10.1097/01.mjt.0000433937.07244.e1
15. Zhang FS, He QZ, Qin CH, Little PJ, Weng JP, Xu SW. Therapeutic potential of colchicine in cardiovascular medicine: A pharmacological review. Acta Pharmacol Sin. 2022;43(9):2173-2190. doi: 10.1038/s41401-021-00835-w
16. Broz P, Dixit VM. Inflammasomes: Mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16(7):407-420. doi: 10.1038/nri.2016.58
17. Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612-632. doi: 10.1038/s41584-019-0277-8
18. Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77. doi: 10.14412/1995-4484-2016-60-77
19. Broderick L, Hoffman HM. IL-1 and autoinflammatory disease: Biology, pathogenesis and therapeutic targeting. Nat Rev Rheumatol. 2022;18(8):448-463. doi: 10.1038/s41584-022-00797-1
20. Klück V, Liu R, Joosten LAB. The role of interleukin-1 family members in hyperuricemia and gout. Joint Bone Spine. 2021;88(2):105092. doi: 10.1016/j.jbspin.2020.105092
21. Toldo S, Abbate A. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. Nat Rev Cardiol. 2024;21(4):219-237. doi: 10.1038/s41569-023-00946-3
22. Mauro AG, Bonaventura A, Vecchié A, Mezzaroma E, Carbone S, Narayan P, et al. The role of NLRP3 inflammasome in pericarditis: Potential for therapeutic approaches. JACC Basic Transl Sci. 2021;6(2):137-150. doi: 10.1016/j.jacbts.2020.11.016
23. Vecchié A, Del Buono MG, Chiabrando GJ, Dentali F, Abbate A, Bonaventura A. Interleukin-1 and the NLRP3 inflammasome in pericardial disease. Curr Cardiol Rep. 2021;23(11):157. doi: 10.1007/s11886-021-01589-x
24. Насонов ЕЛ, Сукмарова ЗН, Попкова ТВ, Белов БС. Проблемы иммунопатологии и перспективы фармакотерапии идиопатического рецидивирующего перикардита: применение ингибитора интерлейкина 1 (Анакинра). Научно-практическая ревматология. 2023;61(1):47-61. doi: 10.47360/1995-4484-2023-47-61
25. Potere N, Abbate A, Kanthi Y, Carrier M, Toldo S, Porreca E, et al. Inflammasome signaling, thromboinflammation, and venous thromboembolism. JACC Basic Transl Sci. 2023;8(9):1245-1261. doi: 10.1016/j.jacbts.2023.03.017
26. Del Buono MG, Bonaventura A, Vecchié A, Moroni F, Golino M, Bressi E, et al. Pathogenic pathways and therapeutic targets of inflammation in heart diseases: A focus on interleukin-1. Eur J Clin Invest. 2024;54(2):e14110. doi: 10.1111/eci.14110
27. Reina-Couto M, Pereira-Terra P, Quelhas-Santos J, Silva-Pereira C, Albino-Teixeira A, Sousa T. Inflammation in human heart failure: Major mediators and therapeutic targets. Front Physiol. 2021;12:746494. doi: 10.3389/fphys.2021.746494
28. Dobrev D, Heijman J, Hiram R, Li N, Nattel S. Inflammatory signalling in atrial cardiomyocytes: A novel unifying principle in atrial fibrillation pathophysiology. Nat Rev Cardiol. 2023;20(3):145-167. doi: 10.1038/s41569-022-00759-w
29. Vora SM, Lieberman J, Wu H. Inflammasome activation at the crux of severe COVID-19. Nat Rev Immunol. 2021;21(11):694-703. doi: 10.1038/s41577-021-00588-x
30. Taylor EW. The mechanism of colchicine inhibition of mitosis I. Kinetics of inhibition and the binding of H3-colchicine. J Cell Biol. 1965;25(1 Suppl):145-160. doi: 10.1083/jcb.25.1.145
31. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-241. doi: 10.1038/nature04516
32. Robertson S, Martínez GJ, Payet CA, Barraclough JY, Celermajer DS, Bursill C, et al. Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. Clin Sci (Lond). 2016;130(14):1237-1246. doi: 10.1042/CS20160090
33. Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T, et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 2013;14(5):454-460. doi: 10.1038/ni.2550
34. Marques-da-Silva C, Chaves MM, Castro NG, Coutinho-Silva R, Guimaraes MZ. Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: Implications for its therapeutic action. Br J Pharmacol. 2011;163(5):912-926. doi: 10.1111/j.1476-5381.2011.01254.x
35. Opstal TSJ, Hoogeveen RM, Fiolet ATL, Silvis MJM, The SHK, Bax WA, et al. Colchicine Attenuates inflammation beyond the inflammasome in chronic coronary artery disease: A LoDoCo2 proteomic substudy. Circulation. 2020;142(20):1996-1998. doi: 10.1161/CIRCULATIONAHA.120.050560
36. Suryono S, Rohman MS, Widjajanto E, Prayitnaningsih S, Wihastuti TA, Oktaviono YH. Effect of colchicine in reducing MMP-9, NOX2, and TGF-β1 after myocardial infarction. BMC Cardiovasc Disord. 2023;23(1):449. doi: 10.1186/s12872-023-03464-9
37. Demidowich AP, Levine JA, Apps R, Cheung FK, Chen J, Fantoni G; CHI Consortium, et al. Colchicine’s effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: Results from a pilot randomized controlled trial. Int J Obes (Lond). 2020;44(8):1793-1799. doi: 10.1038/s41366-020-0598-3
38. Silvis MJM, Fiolet ATL, Opstal TSJ, Dekker M, Suquilanda D, Zivkovic M, et al. Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy. Atherosclerosis. 2021;334:93-100. doi: 10.1016/j.atherosclerosis.2021.08.005
39. Martínez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C, et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc. 2015;4(8):e002128. doi: 10.1161/JAHA.115.002128
40. Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest. 1995;96(2):994-1002. doi: 10.1172/JCI118147
41. Vaidya K, Tucker B, Kurup R, Khandkar C, Pandzic E, Barraclough J, et al. Colchicine inhibits neutrophil extracellular trap formation in patients with acute coronary syndrome after percutaneous coronary intervention. J Am Heart Assoc. 2021;10(1):e018993. doi: 10.1161/JAHA.120.018993
42. Tan Y, Bao X, Li Y, Song G, Lu H, Sun X, et al. Colchicine attenuates microvascular obstruction after myocardial ischemia-reperfusion injury by inhibiting the proliferation of neutrophil in bone marrow. Cardiovasc Drugs Ther. 2023 Dec 8. doi: 10.1007/s10557-023-07528-y
43. Cimmino G, Tarallo R, Conte S, Morello A, Pellegrino G, Loffredo FS, et al. Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1. Vascul Pharmacol. 2018;111:62-70. doi: 10.1016/j.vph.2018.09.004
44. Shah B, Allen N, Harchandani B, Pillinger M, Katz S, Sedlis SP, et al. Erratum to: Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: A pilot study in healthy subjects. Inflammation. 2016;39(1):501. doi: 10.1007/s10753-015-0266-2
45. Cirillo P, Taglialatela V, Pellegrino G, Morello A, Conte S, Di Serafino L, et al. Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. J Thromb Thrombolysis. 2020;50(2):468-472. doi: 10.1007/s11239-020-02121-8
46. Abideen ZU, Pathak DR, Sabanci R, Manu M, Abela GS. The effect of colchicine on cholesterol crystal formation, expansion and morphology: A potential mechanism in atherosclerosis. Front Cardiovasc Med. 2024;11:1345521. doi: 10.3389/fcvm.2024.1345521
47. Schwarz N, Fernando S, Chen YC, Salagaras T, Rao SR, Liyanage S, et al. Colchicine exerts anti-atherosclerotic and -plaque-stabilizing effects targeting foam cell formation. FASEB J. 2023;37(4):e22846. doi: 10.1096/fj.202201469R
48. Zuriaga MA, Yu Z, Matesanz N, Truong B, Asensio-Lopez MC, Uddin MM, et al. Colchicine prevents accelerated atherosclerosis development in TET2-mutant clonal hematopoiesis. Eur Heart J. 2023;4(Suppl 2), ehad655.3264. doi.org/10.1093/eurheartj/ehad655.3264
49. Meyer-Lindemann U, Mauersberger C, Schmidt AC, Moggio A, Hinterdobler J, Li X, et al. Colchicine impacts leukocyte trafficking in atherosclerosis and reduces vascular inflammation. Front Immunol. 2022;13:898690. doi: 10.3389/fimmu.2022.898690
50. Weng JH, Koch PD, Luan HH, Tu HC, Shimada K, Ngan I, et al. Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation. Nat Metab. 2021;3(4):513-522. doi: 10.1038/s42255-021-00366-y
51. Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, et al. Gout. Nat Rev Dis Primers. 2019;5(1):69. doi: 10.1038/s41572-019-0115-y
52. Martinon F. Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev. 2010;233(1):218-232. doi: 10.1111/j.0105-2896.2009.00860.x
53. Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of action of colchicine in the treatment of gout. Clin Ther. 2014;36(10):1465-1479. doi: 10.1016/j.clinthera.2014.07.017
54. McKenzie BJ, Wechalekar MD, Johnston RV, Schlesinger N, Buchbinder R. Colchicine for acute gout. Cochrane Database Syst Rev. 2022;8(8):CD006190. doi: 10.1002/14651858.CD006190.pub3
55. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al.; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447-1461. doi: 10.1002/acr.21773
56. Елисеев МС. Рекомендации Американской коллегии ревматологов (2020 г.) по ведению больных подагрой: что нового и что спорно. Научно-практическая ревматология. 2021;59(2):129-133. doi: 10.47360/1995-4484-2021-129-133
57. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707
58. Елисеев МС. Обновленные рекомендации EULAR по лечению подагры. Комментарии к некоторым позициям. Научно-практическая ревматология. 2017;55(6):600-609. doi: 10.14412/1995-4484-2017-600-609
59. Насонов ЕЛ (ред.). Ревматология. Клинические рекомендации. М.:ГЭОТАР-Медиа;2020.
60. McCarthy GM, Dunne A. Calcium crystal deposition diseases – beyond gout. Nat Rev Rheumatol. 2018;14(10):592-602. doi: 10.1038/s41584-018-0078-5
61. Владимиров СА, Елисеев МС. Современная стратегия лечения болезни депонирования кристаллов пирофосфата кальция. Научно-практическая ревматология. 2018;56(6):746-752. doi: 10.14412/1995-4484-2018-746-752
62. Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA, Jansen TL, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: Management. Ann Rheum Dis. 2011;70(4):571-575. doi: 10.1136/ard.2010.139360
63. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020;72(2):220-233. doi: 10.1002/art.41142
64. Migliore A, Gigliucci G, Alekseeva L, Avasthi S, Bannuru RR, Chevalier X, et al. Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements. Ther Adv Musculoskelet Dis. 2019;11:1759720X19893800. doi: 10.1177/1759720X19893800
65. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-1589. doi: 10.1016/j.joca.2019.06.011
66. Singh A, Molina-Garcia P, Hussain S, Paul A, Das SK, Leung YY, et al. Efficacy and safety of colchicine for the treatment of osteoarthritis: A systematic review and meta-analysis of intervention trials. Clin Rheumatol. 2023;42(3):889-902. doi: 10.1007/s10067-022-06402-w
67. Davis CR, Ruediger CD, Dyer KA, Lester S, Graf SW, Kroon FPB, et al. Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: A randomised, placebo-controlled trial (COLAH). Osteoarthritis Cartilage. 2021;29(2):208-214. doi: 10.1016/j.joca.2020.11.002
68. Vincent TL. IL-1 in osteoarthritis: Time for a critical review of the literature. F1000Res. 2019;8. pii: F1000 Faculty Rev-934. doi: 10.12688/f1000research.18831.1
69. Mobasheri A, van Spil WE, Budd E, Uzieliene I, Bernotiene E, Bay-Jensen AC, et al. Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: Biochemical markers associated with emerging clinical phenotypes and molecular endotypes. Curr Opin Rheumatol. 2019;31(1):80-89. doi: 10.1097/BOR.0000000000000567
70. Conway R, McCarthy GM. Calcium-containing crystals and osteoarthritis: An unhealthy alliance. Curr Rheumatol Rep. 2018;20(3):13. doi: 10.1007/s11926-018-0721-9
71. Frallonardo P, Ramonda R, Peruzzo L, Scanu A, Galozzi P, Tauro L, et al. Basic calcium phosphate and pyrophosphate crystals in early and late osteoarthritis: relationship with clinical indices and inflammation. Clin Rheumatol. 2018;37(10):2847-2853. doi: 10.1007/s10067-018-4166-3
72. McAllister MJ, Chemaly M, Eakin AJ, Gibson DS, McGilligan VE. NLRP3 as a potentially novel biomarker for the management of osteoarthritis. Osteoarthritis Cartilage. 2018;26(5):612-619. doi: 10.1016/j.joca.2018.02.901
73. Heijman MWJ, Fiolet ATL, Mosterd A, Tijssen JGP, van den Bemt BJF, Schut A, et al. Association of low-dose colchicine with incidence of knee and hip replacements: Exploratory analyses from a randomized, controlled, double-blind trial. Ann Intern Med. 2023;176(6):737-742. doi: 10.7326/M23-0289
74. Özen S, Batu ED, Demir S. Familial Mediterranean fever: Recent developments in pathogenesis and new recommendations for management. Front Immunol. 2017;8:253. doi: 10.3389/fimmu.2017.00253
75. Lancieri M, Bustaffa M, Palmeri S, Prigione I, Penco F, Papa R, et al. An update on familial Mediterranean fever. Int J Mol Sci. 2023;24(11):9584. doi: 10.3390/ijms24119584
76. Yin X, Tian F, Wu B, Xu T. Interventions for reducing inflammation in familial Mediterranean fever. Cochrane Database Syst Rev. 2022;3(3):CD010893. doi: 10.1002/14651858.CD010893
77. Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644-651. doi: 10.1136/annrheumdis-2015-208690
78. Ozaltin F, Bilginer Y, Gülhan B, Bajin I, Erdogan O, Hayran M, et al. Diagnostic validity of colchicine in patients with Familial Mediterranean fever. Clin Rheumatol. 2014;33(7):969-674. doi: 10.1007/s10067-014-2598-y
79. Batu ED, Şener S, Arslanoglu Aydin E, Aliyev E, Bagrul İ, Türkmen Ş, et al. A score for predicting colchicine resistance at the time of diagnosis in familial Mediterranean fever: Data from the TURPAID registry. Rheumatology (Oxford). 2024;63(3):791-797. doi: 10.1093/rheumatology/kead242
80. Kilic B, Guler Y, Azman FN, Bostanci E, Ugurlu S. Efficacy and safety of anti-interleukin-1 treatment in familial Mediterranean fever patients: A systematic review and meta-analysis. Rheumatology (Oxford). 2024;63(4):925-935. doi: 10.1093/rheumatology/kead514
81. Butbul Aviel Y, Tatour S, Gershoni Baruch R, Brik R. Colchicine as a therapeutic option in periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome. Semin Arthritis Rheum. 2016;45(4):471-474. doi: 10.1016/j.semarthrit.2015.07.005
82. Adrovic A, Sahin S, Barut K, Kasapcopur O. Familial Mediterranean fever and periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome: Shared features and main differences. Rheumatol Int. 2019;39(1):29-36. doi: 10.1007/s00296-018-4105-2
83. Gaggiano C, Rigante D, Sota J, Grosso S, Cantarini L. Treatment options for periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome in children and adults: A narrative review. Clin Rheumatol. 2019;38(1):11-17. doi: 10.1007/s10067-018-4361-2
84. Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: A contemporary view. Nat Rev Rheumatol. 2018;14(2):119. doi: 10.1038/nrrheum.2018.3
85. Алекберова ЗС. Болезнь Великого шелкового пути: от преданий в XXI век. Научно-практическая ревматология. 2015;53(1):5-8. doi: 10.14412/1995-4484-2015-1-4
86. Gul A. Pathogenesis of Behçet’s disease: Autoinflammatory features and beyond. Semin Immunopathol. 2015;37(4):413-418. doi: 10.1007/s00281-015-0502-8
87. Leccese P, Ozguler Y, Christensen R, Esatoglu SN, Bang D, Bodaghi B, et al. Management of skin, mucosa and joint involvement of Behçet’s syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet’s syndrome. Semin Arthritis Rheum. 2019;48(4):752-762. doi: 10.1016/j.semarthrit.2018.05.008
88. Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808-818. doi: 10.1136/annrheumdis-2018-213225
89. Лисицына ТА, Алекберова ЗС, Голоева Р.Г. Новые рекомендации по ведению пациентов с болезнью/синдромом Бехчета (EULAR, 2018). Научно-практическая ревматология. 2019;57(2):133-141. doi: 10.14412/1995-4484-2019-133-141
90. Pakfetrat A, Mansourian A, Momen-Heravi F, Delavarian Z, Momen-Beitollahi J, Khalilzadeh O, et al. Comparison of colchicine versus prednisolone in recurrent aphthous stomatitis: A double-blind randomized clinical trial. Clin Invest Med. 2010;33(3):E189-E195. doi: 10.25011/cim.v33i3.13725
91. Dastoli S, Nisticò SP, Morrone P, Patruno C, Leo A, Citraro R, et al. Colchicine in managing skin conditions: A systematic review. Pharmaceutics. 2022;14(2):294. doi: 10.3390/pharmaceutics14020294
92. Welzel T, Wildermuth AL, Deschner N, Benseler SM, Kuemmerle-Deschner JB. Colchicine – an effective treatment for children with a clinical diagnosis of autoinflammatory diseases without pathogenic gene variants. Pediatr Rheumatol Online J. 2021;19(1):142. doi: 10.1186/s12969-021-00588-0
93. Kuemmerle-Deschner JB, Schock AL, Hansmann S, Benseler S. Colchicine: An effective treatment option for unclassified autoinflammatory diseases in children. Arthritis Rheumatol. 2018;70(Suppl 9):2277.
94. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al.; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2015;36(42):2921-2964. doi: 10.1093/eurheartj/ehv318
95. Арутюнов ГП, Палеев ФН, Тарловская ЕИ, Моисеева ОМ, Арутюнов АГ, Козиолова НА, и др. Перикардиты. Клинические рекомендации 2022. Российский кардиологический журнал. 2023;28(3):101. doi: 10.15829/1560-4071-2023-5398
96. Rodríguez de la Serna A, Guindo Soldevila J, Martí Claramunt V, Bayés de Luna A. Colchicine for recurrent pericarditis. Lancet. 1987;2(8574):1517. doi: 10.1016/s0140-6736(87)92641-9
97. Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, et al. Colchicine in addition to conventional therapy for acute pericarditis: Results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112(13):2012-2016. doi: 10.1161/CIRCULATIONAHA.105.542738
98. Imazio M, Bobbio M, Cecchi E, Demarie D, Pomari F, Moratti M, et al. Colchicine as first-choice therapy for recurrent pericarditis: Results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005;165(17):1987-1991. doi: 10.1001/archinte.165.17.1987
99. Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, et al.; CORP (COlchicine for Recurrent Pericarditis) Investigators. Colchicine for recurrent pericarditis (CORP): A randomized trial. Ann Intern Med. 2011;155(7):409-414. doi: 10.7326/0003-4819-155-7-201110040-00359
100. Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, et al.; ICAP Investigators. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522-1528. doi: 10.1056/NEJMoa1208536
101. Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): A multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232-2237. doi: 10.1016/S0140-6736(13)62709-9
102. Sambola A, Roca Luque I, Mercé J, Alguersuari J, Francisco-Pascual J, García-Dorado D, et al. Colchicine administered in the first episode of acute idiopathic pericarditis: A randomized multicenter open-label study. Rev Esp Cardiol (Engl Ed). 2019;72(9):709-716. doi: 10.1016/j.rec.2018.11.016
103. Finkelstein Y, Shemesh J, Mahlab K, Abramov D, Bar-El Y, Sagie A, et al. Colchicine for the prevention of postpericardiotomy syndrome. Herz. 2002;27(8):791-794. doi: 10.1007/s00059-002-2376-5
104. Imazio M, Trinchero R, Brucato A, Rovere ME, Gandino A, Cemin R, et al.; COPPS Investigators. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): A multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J. 2010;31(22):2749-2754. doi: 10.1093/eurheartj/ehq319
105. Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, et al.; COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: The COPPS-2 randomized clinical trial. JAMA. 2014;312(10):1016-1023. doi: 10.1001/jama.2014.11026
106. Meurin P, Lelay-Kubas S, Pierre B, Pereira H, Pavy B, Iliou MC, et al.; French Society of Cardiology. Colchicine for postoperative pericardial effusion: A multicentre, double-blind, randomised controlled trial. Heart. 2015;101(21):1711-1716. doi: 10.1136/heartjnl-2015-307827
107. Pan T, Jiang CY, Zhang H, Han XK, Zhang HT, Jiang XY, et al. The low-dose colchicine in patients after non-CABG cardiac surgery: A randomized controlled trial. Crit Care. 2023;27(1):49. doi: 10.1186/s13054-023-04341-9
108. Collini V, De Martino M, Andreis A, De Biasio M, Gaspard F, Paneva E, et al. Efficacy and safety of colchicine for the treatment of myopericarditis. Heart. 2024;110(10):735-739. doi: 10.1136/heartjnl-2023-323484
109. van Osch D, Nathoe HM, Jacob KA, Doevendans PA, van Dijk D, Suyker WJ, et al. Determinants of the postpericardiotomy syndrome: A systematic review. Eur J Clin Invest. 2017;47(6):456-467. doi: 10.1111/eci.12764
110. Imazio M, Brucato A, Ferrazzi P, Spodick DH, Adler Y. Postpericardiotomy syndrome: A proposal for diagnostic criteria. J Cardiovasc Med (Hagerstown). 2013;14(5):351-353. doi: 10.2459/JCM.0b013e328353807d
111. Lutschinger LL, Rigopoulos AG, Schlattmann P, Matiakis M, Sedding D, Schulze PC, et al. Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome. BMC Cardiovasc Disord. 2019;19(1):207. doi: 10.1186/s12872-019-1190-4
112. Alsabri M, Elsayed SM, Elsnhory AB, Abouelmagd K, Ayyad M, Alqeeq BF, et al. Efficacy and safety of colchicine in pediatric pericarditis: A systematic review and future directions. Pediatr Cardiol. 2024 Jul 30. doi: 10.1007/s00246-024-03606-6
113. Somani N, Breur H. The efficacy of corticosteroids, NSAIDs, and colchicine in the treatment of pediatric postoperative pericardial effusion. Pediatr Cardiol. 2022;43(2):279-289. doi: 10.1007/s00246-022-02820-4
114. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135-1143. doi: 10.1161/hc0902.104353
115. Libby P, Loscalzo J, Ridker PM, Farkouh ME, Hsue PY, Fuster V, et al. Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. J Am Coll Cardiol. 2018;72(17):2071-2081. doi: 10.1016/j.jacc.2018.08.1043
116. Libby PJ. An interleukin-1 beta as a target for atherosclerosis therapy: Biological basis of CANTOS and beyond. J Amer Coll Cardiol. 2017;70(18):2278-2289. doi: 10.1016/j.jacc.2017.09.028
117. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145-156. doi: 10.1161/CIRCRESAHA.115.306656
118. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al.; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131. doi: 10.1056/NEJMoa1707914
119. Насонов ЕЛ, Попкова ТВ. Атеросклероз: перспективы противовоспалительной терапии. Терапевтический архив. 2018;90(5):4-12. doi: 10.26442/terarkh201890514-12
120. Gager GM, Biesinger B, Hofer F, Winter MP, Hengstenberg C, Jilma B, et al. Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome. Vascul Pharmacol. 2020;135:106806. doi: 10.1016/j.vph.2020.106806
121. Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res. 2021;128(11):1728-1746. doi: 10.1161/CIRCRESAHA.121.319077
122. Khan MS, Talha KM, Maqsood MH, Rymer JA, Borlaug BA, Docherty KF, et al. Interleukin-6 and cardiovascular events in healthy adults: MESA. JACC Adv. 2024;3(8):101063. doi: 10.1016/j.jacadv.2024.101063
123. McCarthy CP, McEvoy JW, Januzzi JL Jr. Biomarkers in stable coronary artery disease. Am Heart J. 2018;196:82-96. doi: 10.1016/j.ahj.2017.10.016
124. Pan Z, Cheng J, Yang W, Chen L, Wang J. Effect of colchicine on inflammatory markers in patients with coronary artery disease: A meta-analysis of clinical trials. Eur J Pharmacol. 2022;927:175068. doi: 10.1016/j.ejphar.2022.175068
125. Alam M, Kontopantelis E, Mamas MA, Savinova OV, Jhaveri A, Siddiqui E, et al. Meta-analysis of the effect of colchicine on C-reactive protein in patients with acute and chronic coronary syndromes. Coron Artery Dis. 2023;34(3):210-215. doi: 10.1097/MCA.0000000000001220
126. Sun M, Dubé MP, Hennessy T, Schultz CJ, Barhdadi A, Rhainds D, et al. Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: A combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies. Int J Cardiol. 2022;363:20-22. doi: 10.1016/j.ijcard.2022.06.028
127. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-410. doi: 10.1016/j.jacc.2012.10.027
128. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al.; LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838-1847. doi: 10.1056/NEJMoa2021372
129. Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, et al. Colchicine in patients with acute coronary syndrome: The Australian COPS randomized clinical trial. Circulation. 2020;142(20):1890-1900. doi: 10.1161/CIRCULATIONAHA.120.050771
130. Mewton N, Roubille F, Bresson D, Prieur C, Bouleti C, Bochaton T, et al. Effect of colchicine on myocardial injury in acute myocardial infarction. Circulation. 2021;144(11):859-869. doi: 10.1161/CIRCULATIONAHA.121.056177
131. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497-2505. doi: 10.1056/NEJMoa1912388
132. O’Keefe JH Jr, McCallister BD, Bateman TM, Kuhnlein DL, Ligon RW, Hartzler GO. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol. 1992;19(7):1597-1600. doi: 10.1016/0735-1097(92)90624-v
133. Deftereos S, Giannopoulos G, Raisakis K, Kossyvakis C, Kaoukis A, Panagopoulou V, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol. 2013;61(16):1679-1685. doi: 10.1016/j.jacc.2013.01.055
134. Shah B, Pillinger M, Zhong H, Cronstein B, Xia Y, Lorin JD, et al. Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial. Circ Cardiovasc Interv. 2020;13(4):e008717. doi: 10.1161/CIRCINTERVENTIONS.119.008717
135. Cole J, Htun N, Lew R, Freilich M, Quinn S, Layland J. Colchicine to Prevent Periprocedural Myocardial Injury in Percutaneous Coronary Intervention: The COPE-PCI pilot trial. Circ Cardiovasc Interv. 2021;14(5):e009992. doi: 10.1161/CIRCINTERVENTIONS.120.009992
136. Imazio M, Brucato A, Ferrazzi P, Rovere ME, Gandino A, Cemin R, et al.; COPPS Investigators. Colchicine reduces postoperative atrial fibrillation: Results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation. 2011;124(21):2290-2295. doi: 10.1161/CIRCULATIONAHA.111.026153
137. Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, et al.; COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312(10):1016-1023. doi: 10.1001/jama.2014.11026
138. Sarzaeem M, Shayan N, Bagheri J, Jebelli M, Mandegar M. Low dose colchicine in prevention of atrial fibrillation after coronary artery bypass graft: A double blind clinical trial. Tehran Univ Med J. 2014;72:147-154.
139. Zarpelon CS, Netto MC, Jorge JC, Fabris CC, Desengrini D, Jardim Mda S, et al. Colchicine to reduce atrial fibrillation in the postoperative period of myocardial revascularization. Arq Bras Cardiol. 2016;107(1):4-9. doi: 10.5935/abc.20160082
140. Tabbalat RA, Alhaddad I, Hammoudeh A, Khader YS, Khalaf HA, Obaidat M, et al. Effect of Low-dose ColchiciNe on the InciDence of Atrial Fibrillation in Open Heart Surgery Patients: END-AF low dose trial. J Int Med Res. 2020;48(7):300060520939832. doi: 10.1177/0300060520939832
141. Deftereos S, Giannopoulos G, Kossyvakis C, Efremidis M, Panagopoulou V, Kaoukis A, et al. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: A randomized controlled study. J Am Coll Cardiol. 2012;60(18):1790-1796. doi: 10.1016/j.jacc.2012.07.031
142. Deftereos S, Giannopoulos G, Efremidis M, Kossyvakis C, Katsivas A, Panagopoulou V, et al. Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein isolation: Mid-term efficacy and effect on quality of life. Heart Rhythm. 2014;11(4):620-628. doi: 10.1016/j.hrthm.2014.02.002
143. Conen D, Ke Wang M, Popova E, Chan MTV, Landoni G, Cata JP, et al.; COP-AF Investigators. Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): An international randomised trial. Lancet. 2023;402(10413):1627-1635. doi: 10.1016/S0140-6736(23)01689-6
144. Shvartz V, Le T, Enginoev S, Sokolskaya M, Ispiryan A, Shvartz E, et al. Colchicine in Cardiac Surgery: The COCS randomized clinical trial. J Cardiovasc Dev Dis. 2022;9(10):363. doi: 10.3390/jcdd9100363
145. Kelly P, Lemmens R, Weimar C, Walsh C, Purroy F, Barber M, et al. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): A randomised controlled trial. Lancet. 2024;404(10448):125-133. doi: 10.1016/S0140-6736(24)00968-1
146. Li J, Meng X, Shi FD, Jing J, Gu HQ, Jin A, et al.; CHANCE-3 Investigators. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): Multicentre, double blind, randomised, placebo controlled trial. BMJ. 2024;385:e079061. doi: 10.1136/bmj-2023-079061
147. Opstal TSJ, Nidorf SM, Fiolet ATL, Eikelboom JW, Mosterd A, Bax WA, et al. Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial. Int J Cardiol. 2023;372:1-5. doi: 10.1016/j.ijcard.2022.12.026
148. Opstal TSJ, Fiolet ATL, van Broekhoven A, Mosterd A, Eikelboom JW, Nidorf SM, et al.; LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease in relation to prior acute coronary syndrome. J Am Coll Cardiol. 2021;78(9):859-866. doi: 10.1016/j.jacc.2021.06.037
149. Mohammadnia N, Los J, Opstal TSJ, Fiolet ATL, Eikelboom JW, Mosterd A, et al. Colchicine and diabetes in patients with chronic coronary artery disease: Insights from the LoDoCo2 randomized controlled trial. Front Cardiovasc Med. 2023;10:1244529. doi: 10.3389/fcvm.2023.1244529
150. Boczar KE, Shin S, deKemp RA, Dowlatshahi D, Tavoosi A, Wiefels C, et al. The Canadian Study of Arterial Inflammation in Patients with Diabetes and Recent Vascular Events, Evaluation of Colchicine Effectiveness (CADENCE): Protocol for a randomised, double-blind, placebo-controlled trial. BMJ Open. 2023;13(11):e074463. doi: 10.1136/bmjopen-2023-074463
151. Mastrocola R, Penna C, Tullio F, Femminò S, Nigro D, Chiazza F, et al. Pharmacological inhibition of NLRP3 inflammasome attenuates myocardial ischemia/reperfusion injury by activation of RISK and mitochondrial pathways. Oxid Med Cell Longev. 2016;2016:5271251. doi: 10.1155/2016/5271251
152. Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N, et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction: A pilot study. Circulation. 2015;132(15):1395-1403. doi: 10.1161/CIRCULATIONAHA.115.017611
153. Hennessy T, Soh L, Bowman M, Kurup R, Schultz C, Patel S, et al. The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J. 2019;215:62-69. doi: 10.1016/j.ahj.2019.06.003
154. Chen T, Liu G, Yu B. A meta-analysis evaluating efficacy and safety of colchicine for prevention of major cardiovascular events in patients with coronary artery disease. Clin Res Cardiol. 2023;112(11):1487-1505. doi: 10.1007/s00392-023-02254-9
155. Akl E, Sahami N, Labos C, Genest J, Zgheib A, Piazza N, et al. Meta-analysis of randomized trials: Efficacy and safety of colchicine for secondary prevention of cardiovascular disease. J Interv Cardiol. 2024;2024:8646351. doi: 10.1155/2024/8646351
156. Zhou Y, Liu Y, Zeng R, Qiu W, Zhao Y, Zhou Y. Early longterm low-dosage colchicine and major adverse cardiovascular events in patients with acute myocardial infarction: A systematic review and meta-analysis. Front Cardiovasc Med. 2023;10:1194605. doi: 10.3389/fcvm.2023.1194605
157. Herrmann J, Lennon RJ, Barsness GW, Sandhu GS, Gulati R, Best PJ, et al. High sensitivity C-reactive protein and outcomes following percutaneous coronary intervention in contemporary practice. Circ Cardiovasc Interv. 2012;5(6):783-790. doi: 10.1161/CIRCINTERVENTIONS.112.972182
158. Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, et al. White blood cell count and major adverse cardiovascular events after percutaneous coronary intervention in the contemporary era: Insights from the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ Cardiovasc Interv. 2017;10(9):e004981. doi: 10.1161/CIRCINTERVENTIONS.117.004981
159. Chen A, Lu D, Yang Z, Che X, Xia Y, Shao X, et al. Association between NLRP3 inflammasome and periprocedural myocardial injury following elective PCI. Heliyon. 2023;9(8):e19269. doi: 10.1016/j.heliyon.2023.e19269
160. Shah B, Smilowitz NR, Xia Y, Feit F, Katz SD, Zhong J, et al. Major adverse cardiovascular events after colchicine administration before percutaneous coronary intervention: Follow-up of the Colchicine-PCI trial. Am J Cardiol. 2023;204:26-28. doi: 10.1016/j.amjcard.2023.07.029
161. Kommu S, Arepally S. The effect of colchicine on atrial fibrillation: A systematic review and meta-analysis. Cureus. 2023;15(2):e35120. doi: 10.7759/cureus.35120
162. Zhao H, Chen Y, Mao M, Yang J, Chang J. A meta-analysis of colchicine in prevention of atrial fibrillation following cardiothoracic surgery or cardiac intervention. J Cardiothorac Surg. 2022;17(1):224. doi: 10.1186/s13019-022-01958-9
163. Wang X, Peng X, Li Y, Lin R, Liu X, Ruan Y, et al. Colchicine for prevention of post-cardiac surgery and post-pulmonary vein isolation atrial fibrillation: A meta-analysis. Rev Cardiovasc Med. 2022;23(12):387. doi: 10.31083/j.rcm2312387
164. Zietz A, Gorey S, Kelly PJ, Katan M, McCabe JJ. Targeting inflammation to reduce recurrent stroke. Int J Stroke. 2024;19(4):379-387. doi: 10.1177/17474930231207777
165. Samuel M, Tardif JC, Bouabdallaoui N, Khairy P, Dubé MP, Blondeau L, et al. Colchicine for secondary prevention of cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials. Can J Cardiol. 2021;37(5):776-785. doi: 10.1016/j.cjca.2020.10.006
166. Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Jolly SS, Keech AC, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: A systematic review and meta-analysis of randomized trials. Eur Heart J. 2021;42(28):2765-2775
167. Masson W, Lobo M, Molinero G, Masson G, Lavalle-Cobo A. Role of colchicine in stroke prevention: An updated meta-analysis. J Stroke Cerebrovasc Dis. 2020;29(5):104756. doi: 10.1016/j.jstrokecerebrovasdis.2020.104756
168. Yeh JJ, Kuo IL, Yip HT, Hsueh MY, Hsu CY, Kao CH. Effects of colchicine use on ischemic and hemorrhagic stroke risk in diabetic patients with and without gout. Sci Rep. 2022;12(1):9195. doi: 10.1038/s41598-022-13133-0
169. Mishra S, Kass DA. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2021;18(6):400-423. doi: 10.1038/s41569-020-00480-6
170. Deftereos S, Giannopoulos G, Panagopoulou V, Bouras G, Raisakis K, Kossyvakis C, et al. Anti-inflammatory treatment with colchicine in stable chronic heart failure: A prospective, randomized study. JACC Heart Fail. 2014;2(2):131-137. doi: 10.1016/j.jchf.2013.11.006
171. Shchendrygina A, Rachina S, Cherkasova N, Suvorov A, Komarova I, Mukhina N, et al. Colchicine in patients with heart failure and preserved left ventricular ejection fraction: Rationale and design of a prospective, randomised, open-label, crossover clinical trial. Open Heart. 2023;10(2):e002360. doi: 10.1136/openhrt-2023-002360
172. Bourcier L, Bellemare M, Tremblay-Gravel M, Henri C, White M, Bouabdallaoui N. Effects of COLchicine on inflammation, myocardial damage and microvascular dysfunction in heart failure with Preserved Ejection Fraction – the COLpEF trial. Arch Cardiovasc Dis. 2023;15(Suppl):28-59.
173. Sun X, Duan J, Gong C, Feng Y, Hu J, Gu R, et al. Colchicine ameliorates dilated cardiomyopathy via SIRT2-mediated suppression of NLRP3 inflammasome activation. J Am Heart Assoc. 2022;11(13):e025266. doi: 10.1161/JAHA.122.025266
174. Pi S, Xiong S, Yuan Y, Deng H. The role of inflammasome in abdominal aortic aneurysm and its potential drugs. Int J Mol Sci. 2024;25(9):5001. doi: 10.3390/ijms25095001
175. Chen M, Yang D, Zhou Y, Yang C, Lin W, Li J, et al. Colchicine blocks abdominal aortic aneurysm development by maintaining vascular smooth muscle cell homeostasis. Int J Biol Sci. 2024;20(6):2092-2110. doi: 10.7150/ijbs.93544
176. Hu J, Xu J, Zhao J, Liu Y, Huang R, Yao D, et al. Colchicine ameliorates short-term abdominal aortic aneurysms by inhibiting the expression of NLRP3 inflammasome components in mice. Eur J Pharmacol. 2024;964:176297. doi: 10.1016/j.ejphar.2023.176297
177. Crittenden DB, Lehmann RA, Schneck L, Keenan RT, Shah B, Greenberg JD, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39(7):1458-1464. doi: 10.3899/jrheum.111533
178. Shah B, Toprover M, Crittenden DB, Jeurling S, Pike VC, Krasnokutsky S, et al. Colchicine use and incident coronary artery disease in male patients with gout. Can J Cardiol. 2020;36(11):1722-1728. doi: 10.1016/j.cjca.2020.05.026
179. Langevitz P, Livneh A, Neumann L, Buskila D, Shemer J, Amolsky D, et al. Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J. 2001;3(1):9-12.
180. Solomon DH, Liu CC, Kuo IH, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: A cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75(9):1674-1679. doi: 10.1136/annrheumdis-2015-207984
181. Siddiqui MU, Junarta J, Sathyanarayanan S, Kochar K, Ullah W, Fischman DL. Risk of coronary artery disease in patients with gout on treatment with colchicine: A systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2023;45:101191. doi: 10.1016/j.ijcha.2023.101191
182. Ho GH, Toprover M, Crittenden DB, Shah B, Pillinger MH. Colchicine use and major adverse cardiovascular events in male patients with gout and established coronary artery disease: A veterans affairs nested retrospective cohort study. Gout Urate Cryst Dep Dis. 2023;1(1):11-24. doi: 10.3390/gucdd1010003
183. Елисеев МС, Черёмушкина ЕВ, Желябина ОВ, Чикина МН, Капитонова АА, Новикова АА, и др. Влияние терапии колхицином, метотрексатом и гидроксихлорохином на сердечно-сосудистые исходы у пациентов с болезнью депонирования кристаллов пирофосфата кальция. Современная ревматология. 2021;15(6):76-83. doi: 10.14412/1996-7012-2021-6-76-83
184. Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375(6585):1122-1127. doi: 10.1126/science.abm8108
185. van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39-50. doi: 10.1038/s41591-021-01643-9
186. Reyes AZ, Hu KA, Teperman J, Wampler Muskardin TL, Tardif JC, Shah B, et al. Anti-inflammatory therapy for COVID-19 infection: The case for colchicine. Ann Rheum Dis. 2021;80(5):550-557. doi: 10.1136/annrheumdis-2020-219174
187. Lopes MI, Bonjorno LP, Giannini MC, Amaral NB, Menezes PI, Dib SM, et al. Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 2021;7(1):e001455. doi: 10.1136/rmdopen-2020-001455
188. Elshiwy K, Amin GEE, Farres MN, Samir R, Allam MF. The role of colchicine in the management of COVID-19: A meta-analysis. BMC Pulm Med. 2024;24(1):190. doi: 10.1186/s12890-024-03001-0
189. RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet Respir Med. 2021;9(12):1419-1426. doi: 10.1016/S2213-2600(21)00435-5
190. Tardif JC, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pillinger MH, et al.; COLCORONA Investigators. Colchicine for community-treated patients with COVID-19 (COLCORONA): A phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med. 2021;9(8):924-932. doi: 10.1016/S2213-2600(21)00222-8
191. Mikolajewska A, Fischer AL, Piechotta V, Mueller A, Metzendorf MI, Becker M, et al. Colchicine for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;10(10):CD015045. doi: 10.1002/14651858.CD015045
192. Rabbani A, Rafique A, Wang X, Campbell D, Wang D, Brownell N, et al. Colchicine for the treatment of cardiac injury in hospitalized patients with coronavirus disease-19. Front Cardiovasc Med. 2022;9:876718. doi: 10.3389/fcvm.2022.876718
193. Potere N, Garrad E, Kanthi Y, Di Nisio M, Kaplanski G, Bonaventura A, et al. NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis. Cardiovasc Res. 2023;119(11):2046-2060. doi: 10.1093/cvr/cvad084
194. Zuin M, Imazio M, Rigatelli G, Pasquetto G, Bilato C. Risk of incident pericarditis after coronavirus disease 2019 recovery: A systematic review and meta-analysis. J Cardiovasc Med (Hagerstown). 2023;24(11):822-828. doi: 10.2459/JCM.0000000000001536
195. DeVries A, Shambhu S, Sloop S, Overhage JM. One-year adverse outcomes among US adults with post-COVID-19 condition vs those without COVID-19 in a large commercial insurance database. JAMA Health Forum. 2023;4(3):e230010. doi: 10.1001/jamahealthforum.2023.0010
196. Zuin M, Rigatelli G, Bilato C, Porcari A, Merlo M, Roncon L, et al. One-year risk of myocarditis after COVID-19 infection: A systematic review and meta-analysis. Can J Cardiol. 2023;39(6):839-844. doi: 10.1016/j.cjca.2022.12.003
197. Zuin M, Mazzitelli M, Rigatelli G, Bilato C, Cattelan AM. Risk of ischemic stroke in patients recovered from COVID-19 infection: A systematic review and meta-analysis. Eur Stroke J. 2023;8(4):915-922. doi: 10.1177/23969873231190432
198. Toraldo DM, Satriano F, Rollo R, Verdastro G, Imbriani G, Rizzo E, et al. COVID-19 IgG/IgM patterns, early IL-6 elevation and long-term radiological sequelae in 75 patients hospitalized due to interstitial pneumonia followed up from 3 to 12 months. PLoS One. 2022;17(2):e0262911. doi: 10.1371/journal.pone.0262911
199. Yong SJ, Halim A, Halim M, Liu S, Aljeldah M, Al Shammari BR, et al. Inflammatory and vascular biomarkers in post-COVID-19 syndrome: A systematic review and meta-analysis of over 20 biomarkers. Rev Med Virol. 2023;33(2):e2424. doi: 10.1002/rmv.2424
200. Lai YJ, Liu SH, Manachevakul S, Lee TA, Kuo CT, Bello D. Biomarkers in long COVID-19: A systematic review. Front Med (Lausanne). 2023;10:1085988. doi: 10.3389/fmed.2023.1085988
201. Lu J, He Y, Terkeltaub R, Sun M, Ran Z, Xu X, et al. Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination. Ann Rheum Dis. 2022;81(8):1189-1193. doi: 10.1136/annrheumdis-2022-222199
202. Yeh JJ, Hung TW, Lin CL, Chen TT, Liw PX, Yu YL, et al. Colchicine is a weapon for managing the heart disease among interstitial lung disease with viral infection: Have we found the Holy Grail? Front Cardiovasc Med. 2022;9:925211. doi: 10.3389/fcvm.2022.925211
203. Chidambaram V, Kumar A, Sadaf MI, Lu E, Al’Aref SJ, Tarun T, et al. COVID-19 in the initiation and progression of atherosclerosis: Pathophysiology during and beyond the acute phase. JACC Adv. 2024;3(8):101107. doi: 10.1016/j.jacadv.2024.101107
204. Patrono C. Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease. Eur Heart J. 2024;45(27):2362-2376. doi: 10.1093/eurheartj/ehae324
205. Weber C, Habenicht AJR, von Hundelshausen P. Novel mechanisms and therapeutic targets in atherosclerosis: Inflammation and beyond. Eur Heart J. 2023;44(29):2672-2681. doi: 10.1093/eurheartj/ehad304
206. Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Grégoire JC, et al. Cost-effectiveness of low-dose colchicine after myocardial infarction in th Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J Qual Care Clin Outcomes. 2021;7(5):486-495. doi: 10.1093/ehjqcco/qcaa045
207. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al.; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-2397. doi: 10.1056/NEJMoa1410489
208. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al.; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. doi: 10.1056/NEJMoa1615664
209. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al.; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-2107. doi: 10.1056/NEJMoa1801174
210. Buckley LF, Libby P. Colchicine’s role in cardiovascular disease management. Arterioscler Thromb Vasc Biol. 2024;44(5):1031-1041. doi: 10.1161/ATVBAHA.124.319851
211. Nelson K, Fuster V, Ridker PM. Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week. J Am Coll Cardiol. 2023;82(7):648-660. doi: 10.1016/j.jacc.2023.05.055
212. Ridker PM. The time to initiate anti-inflammatory therapy for patients with chronic coronary atherosclerosis has arrived. Circulation. 2023;148(14):1071-1073. doi: 10.1161/CIRCULATIONAHA.123.066510
213. Ridker PM. Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention. Vascul Pharmacol. 2023;153:107238. doi: 10.1016/j.vph.2023.107238
214. Li Z, Lin C, Cai X, Hu S, Lv F, Yang W, et al. Anti-inflammatory therapies were associated with reduced risk of myocardial infarction in patients with established cardiovascular disease or high cardiovascular risks: A systematic review and meta-analysis of randomized controlled trials. Atherosclerosis. 2023;379:117181. doi: 10.1016/j.atherosclerosis.2023.06.972
215. Karpouzas GA, Ormseth SR, van Riel PLCM, Gonzalez-Gay MA, Corrales A, Rantapää-Dahlqvist S, et al. Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis. RMD Open. 2024;10(3):e004546. doi: 10.1136/rmdopen-2024-004546
216. Robinson PC, Terkeltaub R, Pillinger MH, Shah B, Karalis V, Karatza E, et al. Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease. Am J Med. 2022;135(1):32-38. doi: 10.1016/j.amjmed.2021.07.025
217. Алекберова ЗС, Насонов ЕЛ. Перспективы применения колхицина в медицине: новые данные. Научно-практическая ревматология. 2020;58(2):183-190. doi: 10.14412/1995-4484-2020-183-190
218. Nidorf SM, Ben-Chetrit E, Ridker PM. Low-dose colchicine for atherosclerosis: Long-term safety. Eur Heart J. 2024;45(18):1596-1601. doi: 10.1093/eurheartj/ehae208
219. Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC. Adverse events during oral colchicine use: A systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020;22(1):28. doi: 10.1186/s13075-020-2120-7
220. Yeh JJ, Liw PX, Wong YS, Kao HM, Lee CH, Lin CL, et al. The effect of colchicine on cancer risk in patients with immunemediated inflammatory diseases: A time-dependent study based on the Taiwan’s National Health Insurance Research Database. Eur J Med Res. 2024;29(1):245. doi: 10.1186/s40001-024-01836-1
221. Elwood P, Morgan G, Watkins J, Protty M, Mason M, Adams R, et al. Aspirin and cancer treatment: Systematic reviews and meta-analyses of evidence: For and against. Br J Cancer. 2024;130(1):3-8. doi: 10.1038/s41416-023-02506-5
222. Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE; PROMINENT, REDUCE-IT, and STRENGTH Investigators. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: A collaborative analysis of three randomised trials. Lancet. 2023;401(10384):1293-1301. doi: 10.1016/S0140-6736(23)00215-5
223. Ridker PM. From CANTOS to CIRT to COLCOT to Clinic: Will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents? Circulation. 2020;141(10):787-789. doi: 10.1161/CIRCULATIONAHA.119.045256
224. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484225.
225. Institut de Cardiologie de Montréal. Health Canada approval of low-dose colchicine for cardiovascular disease based on the COLCOT study [media release]. 2021. URL: https://www.icmmhi.org/en/pressroom/news/health-canada-approval-low-dosecolchicine-cardiovascular-disease-based-colcot-study (Accessed: DD November 2023).
Рецензия
Для цитирования:
Насонов Е.Л., Драпкина О.М. Колхицин: репозиционирование «античного» лекарства в XXI веке. Научно-практическая ревматология.
For citation:
Nasonov E.L., Drapkina O.M. Colchicine: Repositioning an “ancient” medicine in the 21st century. Rheumatology Science and Practice. (In Russ.)
Просмотров:
423
Послать статью по эл. почте 